# Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide

> **NCT01166113** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fondazione EMN Italy Onlus** · enrollment: 67 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide, Cyclophosphamide, Prednisone

## Key facts

- **NCT ID:** NCT01166113
- **Lead sponsor:** Fondazione EMN Italy Onlus
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-06
- **Final completion:** 2023-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01166113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01166113, "Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01166113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*